Gamma-ECS regulatory subunit: A drug target or biomarker? (G2730)

Target Name: GCLM

NCBI ID: G2730

GCLM

Other Name(s): Gamma-ECS regulatory subunit | Glutamate-cysteine ligase regulatory protein | glutamate-cysteine ligase modifier subunit | Glutamate-cysteine ligase modifier subunit, transcript variant 1 | gamma-ECS regulatory subunit | glutamate-cysteine ligase modifier subunit delta2 alternative splicing | GCLM variant 1 | GCS light chain | Gamma-glutamylcysteine synthetase regulatory subunit | Glutamate--cysteine ligase modifier subunit | Gamma-glutamylcysteine synthetase | Glutamate--cysteine ligase regulatory subunit | gamma-glutamylcysteine synthetase regulatory subunit | GSC light chain | Glutamate-cysteine ligase (gamma-glutamylcysteine synthetase), regulatory (30.8kD) | glutamate-cysteine ligase regulatory protein | GLCLR | glutamate-cysteine ligase (gamma-glutamylcysteine synthetase), regulatory (30.8kD) | Glutamate-cysteine ligase modifier subunit | Glutamate--cysteine ligase regulatory subunit (isoform 1) | GSH0_HUMAN

Gamma-ECS regulatory subunit: A drug target or biomarker?

Gaussian Clustering of Gene Expression (GCLM), also known as Gamma-ECS, is a protein that plays a crucial role in regulating gene expression in various organisms, including humans. GCLM is a subunit of the ESC/TAL-1 gene, which is Responsible for transcribing and translating genetic information within cells. In some diseases, GCLM is studied as a drug target or biomarker. This article will explore the potential of GCLM as a drug target or biomarker and its application in disease research.

1. The role of GCLM

GCLM is a transcription factor that mainly acts on the promoter region of genes and can bind to RNA polymerase and promote gene transcription. The activity of GCLM is subject to a variety of regulations, including transcription factor binding, phosphorylation, ubiquitination, etc. In cells, GCLM is mainly expressed in the nucleus, but also has a small amount of expression in the cytoplasm.

Research shows that GCLM plays an important role in various cancers. For example, the expression level of GCLM is positively correlated with the prognosis of various cancers. In addition, GCLM is related to the invasion and metastasis capabilities of tumor cells and is therefore considered an important mechanism for tumor cells to evade immune surveillance.

2. The potential of GCLM as a drug target

Because GCLM plays an important role in various cancers, it is considered a drug target. Currently, a variety of drugs are under development aimed at inhibiting the activity of GCLM to treat various cancers.

1. Research on anti-tumor drugs

Research on anti-tumor drugs is one of the main methods of current cancer treatment. The mechanism of action of many anti-tumor drugs is to inhibit the growth of tumor cells by interfering with their growth, division, and angiogenesis. However, these drugs often cause serious side effects, so researchers are looking for new drug targets to improve the efficacy of anti-tumor drugs and reduce side effects.

As a new drug target, GCLM has good anti-tumor potential. Studies have shown that GCLM inhibitors can inhibit the growth and metastasis of tumor cells, thereby improving the survival rate of tumor patients. In addition, GCLM inhibitors can also reduce the drug resistance of tumor cells, thereby extending the effectiveness of the drug.

2. GCLM and immune evasion of tumor cells

Tumor cells often have immune evasion capabilities, which means they can evade attack by the immune system. As an important transcription factor, GCLM may be involved in the immune evasion of tumor cells. Therefore, inhibiting the activity of GCLM may help enhance the immunogenicity of tumor cells, thereby making tumor cells more susceptible to attack by the immune system.

3. Application of GCLM as a biomarker

GCLM can be used as a biomarker for detection and diagnosis. For example, the expression level of GCLM can be used to detect tumor invasiveness and metastasis. In tumor patients, the expression level of GCLM usually changes, so the growth and metastasis status of the tumor can be assessed by detecting the expression level of GCLM.

In addition, GCLM can also be used to detect drug resistance in tumors. As tumor treatment progresses, tumor cells may develop drug resistance, resulting in a decrease in therapeutic efficacy. As an important transcription factor, GCLM may be involved in the drug resistance of tumor cells. Therefore, detecting the expression level of GCLM can be used to evaluate tumor drug resistance and guide treatment selection.

4. Summary

As a transcription factor, GCLM plays a crucial role in cells. The expression level of GCLM is related to the prognosis and progression of various cancers and is therefore considered a drug target. In addition, GCLM can also be used as a biomarker for detection and diagnosis. In the future, with further research on GCLM, GCLM may provide new ideas and methods for the treatment of various cancers.

Protein Name: Glutamate-cysteine Ligase Modifier Subunit

The "GCLM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GCLM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets